Stryker OP-1 royalties
This article was originally published in The Gray Sheet
Executive Summary
Curis enters agreement eliminating all future royalties to Stryker related to osteogenic protein-1 sales, the firms say Oct. 1. Under the terms of the deal, Curis receives a one-time $14 mil. cash transfer from Stryker, which will amortize the payment over 15 years...